Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, anemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with single lineage dysplasia, myeloid leukemia, neoplasm	Recruiting	Phase 2	2026-05-26		NCT07607418

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Ruijin Hospital	454

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Ruijin Hospital	Shanghai	China	28

Clinical trials